ERBB2 and cyclic hematopoiesis: Previous pancancer studies3 suggested inferior OS for patients with CH-PD, but these analyses failed to account for phenotypes with outlying therapeutic benefit (ERBB2, MSI-H, etc) or cancer stage at diagnosis.